| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Matteo Manca, Heidi G Standke, Danielle F Browne, Mikayla L Huntley, Olivia R Thomas, Christina D Orrú, Andrew G Hughson, Yongya Kim, Jing Zhang, Curtis Tatsuoka, Xiongwei Zhu, Annie Hiniker, David G Coughlin, Douglas Galasko, Allison Krau. Tau seeds occur before earliest Alzheimer's changes and are prevalent across neurodegenerative diseases. Acta neuropathologica. 2023-05-08. PMID:37154939. |
this study suggests 3r/4r tau seeds are widespread even prior to the earliest stages of alzheimer's disease changes, including in normal, and even young individuals, with prevalence across multiple neurodegenerative diseases to further define disease subtypes. |
2023-05-08 |
2023-08-14 |
Not clear |
| Antoine Leuzy, Alexa Pichet Binette, Jacob W Vogel, Gregory Klein, Edilio Borroni, Matteo Tonietto, Olof Strandberg, Niklas Mattsson-Carlgren, Sebastian Palmqvist, Michael J Pontecorvo, Leonardo Iaccarino, Erik Stomrud, Rik Ossenkoppele, Ruben Smith, Oskar Hansso. Comparison of Group-Level and Individualized Brain Regions for Measuring Change in Longitudinal Tau Positron Emission Tomography in Alzheimer Disease. JAMA neurology. 2023-05-08. PMID:37155176. |
comparison of group-level and individualized brain regions for measuring change in longitudinal tau positron emission tomography in alzheimer disease. |
2023-05-08 |
2023-08-14 |
human |
| Antoine Leuzy, Alexa Pichet Binette, Jacob W Vogel, Gregory Klein, Edilio Borroni, Matteo Tonietto, Olof Strandberg, Niklas Mattsson-Carlgren, Sebastian Palmqvist, Michael J Pontecorvo, Leonardo Iaccarino, Erik Stomrud, Rik Ossenkoppele, Ruben Smith, Oskar Hansso. Comparison of Group-Level and Individualized Brain Regions for Measuring Change in Longitudinal Tau Positron Emission Tomography in Alzheimer Disease. JAMA neurology. 2023-05-08. PMID:37155176. |
longitudinal tau positron emission tomography (pet) is a relevant outcome in clinical trials evaluating disease-modifying therapies in alzheimer disease (ad). |
2023-05-08 |
2023-08-14 |
human |
| Shu-Mei Wang, Jiunn-Jye Chuu, Ching-Kuo Lee, Chia-Yu Chan. Exploring the therapeutic efficacy of Heliyon. vol 9. issue 5. 2023-05-05. PMID:37144207. |
exploring the therapeutic efficacy of alzheimer's disease (ad) is one of the neurodegenerative disorders, the hallmarks of which include deposits of extracellular beta-amyloid (aβ) as well as intracellular tau neurofibrillary tangles (nfts) tangles. |
2023-05-05 |
2023-08-14 |
Not clear |
| Shannon E Hill, David Beaulieu-Abdelahad, Andrea Lemus, Jack M Webster, Santiago Rodriguez Ospina, April L Darling, Mackenzie D Martin, Shreya Patel, Liznair Bridenstine, Ronald Swonger, Steven Paul, Roy Blackburn, Laurent Calcul, Chad A Dickey, James W Leahy, Laura J Blai. ACS chemical biology. 2023-05-05. PMID:37144894. |
the accumulation and aggregation of the microtubule-associated protein tau (tau) into intracellular neuronal tangles are a hallmark of a range of progressive neurodegenerative tauopathies, including alzheimer's disease (ad), frontotemporal dementia, pick's disease, and progressive supranuclear palsy. |
2023-05-05 |
2023-08-14 |
Not clear |
| Joseph B Rayma. Focusing on oligomeric tau as a therapeutic target in Alzheimer's disease and other tauopathies. Expert opinion on therapeutic targets. 2023-05-04. PMID:37140480. |
focusing on oligomeric tau as a therapeutic target in alzheimer's disease and other tauopathies. |
2023-05-04 |
2023-08-14 |
Not clear |
| Joseph B Rayma. Focusing on oligomeric tau as a therapeutic target in Alzheimer's disease and other tauopathies. Expert opinion on therapeutic targets. 2023-05-04. PMID:37140480. |
tau pathology is a hallmark of primary tauopathies, such as progressive supranuclear palsy (psp), corticobasal syndrome (cbs), and subtypes of frontotemporal dementia (ftd), as well as secondary tauopathies, such as alzheimer's disease (ad). |
2023-05-04 |
2023-08-14 |
Not clear |
| F A Concepcion, N A Ekstrom, M N Khan, O O Estes, N P Poolo. Progressive Dysregulation of Tau Phosphorylation in an Animal Model of Temporal Lobe Epilepsy. Neuroscience. 2023-05-04. PMID:37142182. |
tau is an intracellular protein known to undergo hyperphosphorylation and subsequent neuro-toxic aggregation in alzheimer's disease (ad). |
2023-05-04 |
2023-08-14 |
human |
| Belfin Robinson, Shankar Bhamidi, Eran Daya. The spatial distribution of coupling between tau and neurodegeneration in amyloid-β positive mild cognitive impairment. medRxiv : the preprint server for health sciences. 2023-05-03. PMID:37131677. |
synergies between amyloid-β (aβ), tau, and neurodegeneration persist along the alzheimer's disease (ad) continuum. |
2023-05-03 |
2023-08-14 |
Not clear |
| Jiaying Lu, Zhengwei Zhang, Ping Wu, Xiaoniu Liang, Huiwei Zhang, Jimin Hong, Christoph Clement, Tzu-Chen Yen, Saineng Ding, Min Wang, Zhenxu Xiao, Axel Rominger, Kuangyu Shi, Yihui Guan, Chuantao Zuo, Qianhua Zha. The heterogeneity of asymmetric tau distribution is associated with an early age at onset and poor prognosis in Alzheimer's disease. NeuroImage. Clinical. vol 38. 2023-05-03. PMID:37137254. |
the heterogeneity of asymmetric tau distribution is associated with an early age at onset and poor prognosis in alzheimer's disease. |
2023-05-03 |
2023-08-14 |
Not clear |
| Julien Lagarde, Pauline Olivieri, Matteo Tonietto, Sébastian Rodrigo, Philippe Gervais, Fabien Caillé, Martin Moussion, Michel Bottlaender, Marie Sarazi. Could tau-PET imaging contribute to a better understanding of the different patterns of clinical progression in Alzheimer's disease? A 2-year longitudinal study. Alzheimer's research & therapy. vol 15. issue 1. 2023-05-03. PMID:37138309. |
monitoring the progression of tau pathology makes it possible to study the clinical diversity of alzheimer's disease. |
2023-05-03 |
2023-08-14 |
Not clear |
| Andrea Arsiccio, Xikun Liu, Pritam Ganguly, Steven K Buratto, Michael T Bowers, Joan-Emma She. Effect of Cosolutes on the Aggregation of a Tau Fragment: A Combined Experimental and Simulation Approach. The journal of physical chemistry. B. 2023-05-02. PMID:37129599. |
the intrinsically disordered protein tau represents the main component of neurofibrillary tangles that are a hallmark of alzheimer's disease. |
2023-05-02 |
2023-08-14 |
Not clear |
| Yingmei Tang, Minghui Cao, Yunhua Li, Yuting Lin, Xiaoyan Wu, Meiwei Che. Altered structural covariance of locus coeruleus in individuals with significant memory concern and patients with mild cognitive impairment. Cerebral cortex (New York, N.Y. : 1991). 2023-05-02. PMID:37130822. |
the locus coeruleus (lc) is the site where tau accumulation is preferentially observed pathologically in alzheimer's disease (ad) patients, but the changes in gray matter co-alteration patterns between the lc and the whole brain in the predementia phase of ad remain unclear. |
2023-05-02 |
2023-08-14 |
human |
| Kumarappan Chidambara. Identification of BACE-1 Inhibitors against Alzheimer's Disease through E-Pharmacophore-Based Virtual Screening and Molecular Dynamics Simulation Studies: An Insilco Approach. Life (Basel, Switzerland). vol 13. issue 4. 2023-04-28. PMID:37109481. |
alzheimer is a severe memory and cognitive impairment neurodegenerative disease that is the most common cause of dementia worldwide and characterized by the pathological accumulation of tau protein and amyloid-beta peptides. |
2023-04-28 |
2023-08-14 |
Not clear |
| Reem M Fars. The Role of Mitochondrial Dysfunction in Alzheimer's: Molecular Defects and Mitophagy-Enhancing Approaches. Life (Basel, Switzerland). vol 13. issue 4. 2023-04-28. PMID:37109499. |
alzheimer's disease (ad), a progressive and chronic neurodegenerative syndrome, is categorized by cognitive and memory damage caused by the aggregations of abnormal proteins, specifically including tau proteins and β-amyloid in brain tissue. |
2023-04-28 |
2023-08-14 |
Not clear |
| Avinash H Bansode, Bhuvanachandra Bhoopal, Krishna Kumar Gollapelli, Naresh Damuka, Ivan Krizan, Mack Miller, Suzanne Craft, Akiva Mintz, Kiran Kumar Solingapuram Sa. Binding Parameters of [ Pharmaceuticals (Basel, Switzerland). vol 16. issue 4. 2023-04-28. PMID:37111252. |
binding parameters of [ impairment and/or destabilization of neuronal microtubules (mts) resulting from hyper-phosphorylation of the tau proteins is implicated in many pathologies, including alzheimer's disease (ad), parkinson's disease and other neurological disorders. |
2023-04-28 |
2023-08-14 |
Not clear |
| Haishu Chen, Jinan Xu, Hanyuan Xu, Tiancheng Luo, Yihao Li, Ke Jiang, Yangping Shentu, Zhiqian Ton. New Insights into Alzheimer's Disease: Novel Pathogenesis, Drug Target and Delivery. Pharmaceutics. vol 15. issue 4. 2023-04-28. PMID:37111618. |
alzheimer's disease (ad), the most common type of dementia, is characterized by senile plaques composed of amyloid β protein (aβ) and neurofilament tangles derived from the hyperphosphorylation of tau protein. |
2023-04-28 |
2023-08-14 |
Not clear |
| Musa O Iliyasu, Sunday A Musa, Sunday B Oladele, Abdullahi I Iliy. Amyloid-beta aggregation implicates multiple pathways in Alzheimer's disease: Understanding the mechanisms. Frontiers in neuroscience. vol 17. 2023-04-28. PMID:37113145. |
alzheimer's disease (ad) is a progressive neurodegenerative condition characterized by tau pathology and accumulations of neurofibrillary tangles (nfts) along with amyloid-beta (aβ). |
2023-04-28 |
2023-08-14 |
Not clear |
| Hannah M Tayler, Robert MacLachlan, Özge Güzel, J Scott Miners, Seth Lov. Elevated late-life blood pressure may maintain brain oxygenation and slow amyloid-β accumulation at the expense of cerebral vascular damage. Brain communications. vol 5. issue 2. 2023-04-28. PMID:37113314. |
we have investigated the relationship of blood pressure and hypertensive status during late life (after 65 years) to post-mortem markers of alzheimer's disease (amyloid-β and tau loads); arteriolosclerosis and cerebral amyloid angiopathy; and to biochemical measures of ante-mortem cerebral oxygenation (the myelin-associated glycoprotein:proteolipid protein-1 ratio, which is reduced in chronically hypoperfused brain tissue, and the level of vascular endothelial growth factor-a, which is upregulated by tissue hypoxia); blood-brain barrier damage (indicated by an increase in parenchymal fibrinogen); and pericyte content (platelet-derived growth factor receptor β, which declines with pericyte loss), in alzheimer's disease ( |
2023-04-28 |
2023-08-14 |
Not clear |
| Jasen F Saad, Fawzy A Saa. Gene Therapy for Alzheimer and Parkinson Diseases. Current gene therapy. 2023-04-28. PMID:37114789. |
β-amyloid peptides, α-synuclein, and tau aggregates start building up two decades before the onset of alzheimer and parkinson diseases. |
2023-04-28 |
2023-08-14 |
Not clear |